ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome [Yahoo! Finance]
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target raised by analysts at Stifel Nicolaus from $24.00 to $25.00. They now have a "hold" rating on the stock.
ACADIA Pharmaceuticals (ACAD) Is Up 9.6% After Earnings Beat And NUPLAZID Patent Extension News [Yahoo! Finance]